TABLE 3

Respiratory drug use and healthcare use in the 12 months preceding and in the 12 months following omalizumab initiation (overall population and stratified into patients fulfilling eligibility criteria versus those who did not)

Patients initiating treatment with omalizumab (n=1681)Patients eligible for omalizumab treatment (n=380)Patients not eligible for omalizumab treatment (n=1301)
YBYAYA−YBp-valueYBYAYA−YBp-valueYBYAYA−YBp-value
Patients visiting ED and treated with SCS68 (4%)32 (2%)−2%0.0002#34 (9%)12 (3%)−6%0.0009#34 (3%)20 (2%)−1%0.0433#
Patients hospitalised and treated with SCS404 (24%)258 (15%)−9%<0.0001#154 (41%)78 (21%)−20%<0.0001#250 (19%)180 (14%)−5%<0.0001#
Patients treated with SCS as maintenance treatment (>180 DDD per year)520 (31%)327 (19%)−11%<0.0001#220 (58%)135 (36%)−22%<0.0001#300 (23%)192 (15%)−8%<0.0001#
DDD of respiratory drugs per patient per year median
 ICS (with or without LABA)23021100.3981390378−300.000918018000.2082
 Rescue therapy (SABA and/or SAMA)85670<0.0002173140−60.2217755000.0003
 LTRAs1409800.052825824100.0334999800.2998
Number of consultations median
 Pulmonary physician394<0.00014105<0.0001384<0.0001
 Other physicians6500.08911312−10.0249101000.5037

YB: 12 months before omalizumab initiation; YA: 12 months after omalizumab initiation; ED: emergency department; SCS: systemic corticosteroid; DDD: defined daily dose; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; SABA: short-acting β2-agonist; SAMA: short-acting muscarinic antagonist; LTRA: leukotriene receptor antagonist. #: McNemar test; : Wilcoxon rank-sum test.